SCHEMBL5537666

SCHEMBL5537666

O=[C]OCc1ccc(SC(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRZ1 P23471 4/20 0.59
PTPN1 P18031 2/20 0.50
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
KIF11 P52732 1/20 0.35
KCNK2 O95069 1/20 0.34
KCNK10 P57789 1/20 0.34
HCRTR1 O43613 2/20 0.33
HCRTR2 O43614 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
RXRA P19793 1/20 0.33
HNF4A P41235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541929 0.83 PTPRZ1 (0.47) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL514240 0.80 FFAR4 (0.44) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5535863 0.80 PTPRZ1 (0.45) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5537818 0.79 PTPRZ1 (0.44) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL6002206 0.79 PTPRZ1 (0.69) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5536724 0.78 PTPRZ1 (0.43) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5536681 0.78 PTPRZ1 (0.43) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL13232623 0.76 PTPRZ1 (0.65) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5537390 0.76 SLC6A4 (0.47)
SCHEMBL2094884 0.76 IDO1 (0.57) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PTPRZ1 2595/4885PTPN1 1427/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.